MX2021005371A - Objetivo de tepoxalina de cánceres que sobre expresan abcb1. - Google Patents

Objetivo de tepoxalina de cánceres que sobre expresan abcb1.

Info

Publication number
MX2021005371A
MX2021005371A MX2021005371A MX2021005371A MX2021005371A MX 2021005371 A MX2021005371 A MX 2021005371A MX 2021005371 A MX2021005371 A MX 2021005371A MX 2021005371 A MX2021005371 A MX 2021005371A MX 2021005371 A MX2021005371 A MX 2021005371A
Authority
MX
Mexico
Prior art keywords
tepoxalin
cancer
abcb1
chemotherapeutic
compositions
Prior art date
Application number
MX2021005371A
Other languages
English (en)
Inventor
Todd Golub
Steven Corsello
Ryan Spangler
Rohith Nagari
Original Assignee
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc filed Critical Broad Inst Inc
Publication of MX2021005371A publication Critical patent/MX2021005371A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para el diagnóstico y tratamiento o prevención de cánceres que presentan expresión y/o amplificación elevada del transportador de ABCB1 (MDR1), opcionalmente por razones relacionadas con el desarrollo de resistencia al quimioterapéutico que ha ocurrido durante el tratamiento con un fármaco quimioterapéutico inicial. En particular, la presente descripción proporciona identificación de un cáncer que posee expresión elevada de ABCB1 y/o que presenta resistencia a un fármaco quimioterapéutico no tepoxalina, y seleccionar y/o administrar tepoxalina, un derivado de tepoxalina y/o metabolito del mismo como un agente terapéutico para tal cáncer y/o sujeto que tiene o en riesgo de desarrollar tal cáncer. También se proporcionan métodos y composiciones para terapias que combinan tal tepoxalina o compuestos relacionados con tepoxalina con otras terapias para el cáncer y/o agentes qumioterapéuticos.
MX2021005371A 2018-11-09 2019-11-08 Objetivo de tepoxalina de cánceres que sobre expresan abcb1. MX2021005371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862758294P 2018-11-09 2018-11-09
PCT/US2019/060516 WO2020097492A1 (en) 2018-11-09 2019-11-08 Tepoxalin targeting of abcb1 overexpressing cancers

Publications (1)

Publication Number Publication Date
MX2021005371A true MX2021005371A (es) 2021-10-13

Family

ID=70612273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005371A MX2021005371A (es) 2018-11-09 2019-11-08 Objetivo de tepoxalina de cánceres que sobre expresan abcb1.

Country Status (4)

Country Link
US (1) US20220065864A1 (es)
EP (1) EP3877056A4 (es)
MX (1) MX2021005371A (es)
WO (1) WO2020097492A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196907A1 (en) * 2009-01-31 2010-08-05 Abbott Laboratories Markers to predict and monitor response to aurora kinase b inhibitor therapy

Also Published As

Publication number Publication date
US20220065864A1 (en) 2022-03-03
EP3877056A4 (en) 2022-08-17
EP3877056A1 (en) 2021-09-15
WO2020097492A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12017501857A1 (en) Pd-l1 antagonist combination treatments
MX2019012462A (es) Terapia combinada.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2017007321A (es) Terapias de combinacion.
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2019001286A (es) Composicion de cannabis.
NZ754865A (en) Combination therapy for the treatment of cancer
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
WO2019197605A3 (en) Drug combinations for use in the treatment of ras-mutant cancer
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2016100738A3 (en) Antifibrotic activity of gas6 inhibitor
ZA201907225B (en) Treatment of her2 positive cancers
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
JP2019532047A5 (es)
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
MY197419A (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
MX2020011453A (es) Combinaciones para tratar el cancer.
WO2019147338A3 (en) Radiopharmaceuticals and methods of use thereof
MX2019005212A (es) Vacuna de adn dirigida a wt1 para terapia de combinacion.
MX2021005371A (es) Objetivo de tepoxalina de cánceres que sobre expresan abcb1.
MX2018010096A (es) Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos.